The management of gastrointestinal disorders remains a critical area in pediatrics, particularly concerning infants (children of the first year of life). With high rates of morbidity and mortality associated with diarrheal diseases globally, finding effective and safe therapies is essential. This retrospective study aimed to precisely evaluate the clinical effectiveness and safety profile of the enterosorbent Polymethylsiloxane polyhydrate (Enterosgel) when used as part of a comprehensive treatment plan for non-infectious digestive pathologies in this vulnerable age group.

Methods and Participants:

The analysis included two groups of patients under one year old:

Main Group: 38 infants who received standard complex treatment plus the enterosorbent Enterosgel.

Comparison Group: 12 infants who received standard complex treatment only.

Patients were treated for various non-infectious conditions, including gastroenteritis, colitis, and liver diseases. The primary efficacy criteria assessed were the resolution of intoxication symptoms, stool normalization, and the duration of hospital stay. Safety was monitored through clinical blood tests and observation for side effects.

Key Clinical Findings:

The inclusion of Enterosgel led to a markedly faster recovery:

Symptom Resolution: Patients in the main group achieved a significantly more rapid relief of intoxication symptoms (such as fever and malaise) and, critically, faster normalization of stool consistency. Pathological impurities in the stool, like mucus and green matter, disappeared faster when Enterosgel was administered.

Duration of Hospital Stay: The most compelling finding was the substantial reduction in the length of hospitalization. Infants receiving Enterosgel spent an average of 5 days in the hospital, compared to 11 days in the comparison group—a reduction by more than two times.

Safety Profile: The therapy demonstrated excellent tolerability. No adverse events (such as allergic reactions or digestive side effects) were observed, and no negative changes were detected in clinical blood test parameters (hemoglobin, leukocytes, etc.).

Conclusion:

This research confirms the high therapeutic efficacy and safety of Polymethylsiloxane polyhydrate (Enterosgel) in infants with non-infectious digestive diseases. Its ability to accelerate the resolution of clinical symptoms and significantly reduce the time spent in the hospital strongly supports its recommendation for complex pediatric treatment.

 Full Article: For a full understanding of the therapeutic approach, and to review the detailed data, statistical graphs, and tables supporting these significant conclusions, please read the complete article: Full Article